Cannabis made another leap forward in 1964 when Israeli scientist Dr. Raphael Mechoulam identified the structure of delta-9-tetrahydrocannabinol, or THC. This discovery earned him godfather status of modern cannabis. This particular discovery allowed science to understand THC’s nature as a psychoactive compound in cannabis as well as CBD’s non-intoxicating but vastly therapeutic benefits.

"Given these data limitations, available trade statistics indicate that the value of U.S. imports under categories actually labeled 'hemp,' such as hemp seeds and fibers—which are more often used as inputs for use in further manufacturing—was nearly $78.2 million in 2015. Compared to 2005, when the value of imports totaled $5.6 million, imported hemp products for use as inputs and ingredients has increased sharply. However, import volumes for other products, such as hemp oil and fabrics, are lower (Table 1). Trade data are not available for finished products, such as hempbased clothing or other products including construction materials, carpets, or paper products.
Even as the research proceeds, thousands of people are using CBD as medicine. A British pharmaceutical company, GW Pharma, has developed two CBD drugs: Sativex, which contains a 1-to-1 ratio of CBD and THC, and Epidiolex, which is pure CBD. The former is prescribed for the painful muscle spasms that occur in multiple sclerosis, while the latter is aimed at childhood seizures. Sativex is not available in the United States, but it is approved in 29 other countries, including Canada, England and Israel.
Last May, not long before Canada legalized the recreational use of marijuana, Beau Kilmer, a drug-policy expert with the RAND Corporation, testified before the Canadian Parliament. He warned that the fastest-growing segment of the legal market in Washington State was extracts for inhalation, and that the mean THC concentration for those products was more than sixty-five per cent. “We know little about the health consequences—risks and benefits—of many of the cannabis products likely to be sold in nonmedical markets,” he said. Nor did we know how higher-potency products would affect THC consumption.
Cannabis terpenoids also display numerous attributes that may be germane to pain treatment (McPartland and Russo 2001). Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone (Rao et al 1990), suggesting an opioid-like mechanism. It also blocks inflammation via PGE-2 (Lorenzetti et al 1991). The cannabis sesquiterpenoid β-caryophyllene shows increasing promise in this regard. It is anti-inflammatory comparable to phenylbutazone via PGE-1 (Basile et al 1988), but simultaneously acts as a gastric cytoprotective (Tambe et al 1996). The analgesic attributes of β-caryophyllene are increasingly credible with the discovery that it is a selective CB2 agonist (Gertsch et al 2007), with possibly broad clinical applications. α-Pinene also inhibits PGE-1 (Gil et al 1989), while linalool displays local anesthetic effects (Re et al 2000).
"Hemp fibers are used in fabrics and textiles, yarns and spun fibers, paper, carpeting, home furnishings, construction and insulation materials, auto parts, and composites. Hurds are used in animal bedding, material inputs, papermaking, and oil absorbents. Hemp seed and oilcake are used in a range of foods and beverages (e.g., salad and cooking oil and hemp dairy alternatives) and can be an alternative food and feed protein source.8 Oil from the crushed hemp seed is used in soap, shampoo, lotions, bath gels, and cosmetics.9 Hemp is also being used in nutritional supplements and in medicinal and therapeutic products, including pharmaceuticals. It is also used in a range of composite products. Hempcrete (a mixture of hemp hurds and lime products) is being used as a building material. Hemp is also used as a lightweight insulating material and in hemp plastics and related composites for use as a fiberglass alternative by the automotive and aviation sectors.10 Hemp is also promoted as a potential biodiesel feedstock11 and cover crop."
Toggle navigationNewsConditionsConditionsADHDAllergic rhinitisAlzheimer's diseaseAnxietyArthritisAsthmaAutismBowel cancerBreast cancerCancerChesty coughsChickenpoxChlamydiaCholesterolCoeliac diseaseCommon coldConstipationCOPDDepressionDiabetesDiverticulitisEpilepsyFatty liverFibromyalgiaGenital herpesGORD (reflux)GoutHaemorrhoidsHair lossHeart attackHepatitisHiatus herniaHigh blood pressureHIV and AIDSImpotenceMenopauseMigraineNeuropathic painOsteoporosisPainPeptic ulcersPneumoniaProstate cancerScabiesSchizophreniaSciaticaShinglesSinusitisSkin cancerStrokeThyroid gland disordersUrticaria (hives)Vaginal thrushVasectomyVertigoVulval problemsWhooping coughMedicinesMedicinesAugmentinAvilChlorsigDaklinzaDuromineEndepEndoneHarvoniLevlenLyricaMersyndolMetrogylPanadeine FortePanefcortelonePrimolutRestavitSovaldiStemetilViagraZentelFind a MedicineMedicines CentreSymptomsSymptomsBack painChildhood rashesCommon coldDepressionFeverFibromyalgiaHeart attackHeel painHerpesLeg acheLeg crampsSciaticaShinglesStrokeVaginal thrushVertigoMore symptomsLifestyleHealthy LifestyleAddictionsAlcoholCholesterolExerciseHealthy eatingHealthy WeightHeart healthImmunisationSleepSmokingStress Health Centres Nutrition & WeightSports & FitnessTools Medical Dictionary Medical Dictionary

Some immediate undesired side effects include a decrease in short-term memory, dry mouth, impaired motor skills and reddening of the eyes.[50] Aside from a subjective change in perception and mood, the most common short-term physical and neurological effects include increased heart rate, increased appetite and consumption of food, lowered blood pressure, impairment of short-term and working memory,[51][52] psychomotor coordination, and concentration.

Cannabidiol, a non-euphoriant phytocannabinoid common in certain strains, shares neuroprotective effects with THC, inhibits glutamate neurotoxicity, and displays antioxidant activity greater than ascorbic acid (vitamin C) or tocopherol (vitamin E) (Hampson et al 1998). While THC has no activity at vanilloid receptors, CBD, like AEA, is a TRPV1 agonist that inhibits fatty acid amidohydrolase (FAAH), AEA’s hydrolytic enzyme, and also weakly inhibits AEA reuptake (Bisogno et al 2001). These activities reinforce the conception of CBD as an endocannabinoid modulator, the first clinically available (Russo and Guy 2006). CBD additionally affects THC function by inhibiting first pass hepatic metabolism to the possibly more psychoactive 11-hydroxy-THC, prolonging its half-life, and reducing associated intoxication, panic, anxiety and tachycardia (Russo and Guy 2006). Additionally, CBD is able to inhibit tumor necrosis factor-alpha (TNF-α) in its own right in a rodent model of rheumatoid arthritis (Malfait et al 2000). At a time when great concern is accruing in relation to NSAIDs in relation to COX-1 inhibition (gastrointestinal ulcers and bleeding) and COX-2 inhibition (myocardial infarction and cerebrovascular accidents), CBD, like THC, inhibits neither enzyme at pharmacologically relevant doses (Stott et al 2005a). A new explanation of inflammatory and analgesic effects of CBD has recently come to light with the discovery that it is able to promote signaling of the adenosine receptor A2A by inhibiting the adenosine transporter (Carrier et al 2006).
States have passed laws creating or allowing for the establishment of industrial hemp research or pilot programs. State agencies and institutions of higher education administer these programs in order to study the cultivation, processing, and economics of industrial hemp. Pilot programs may be limited to a certain period of time and may require periodic reporting from participants and state agencies. Some states establish specific regulatory agencies or committees, rules, and goals to oversee the research programs. States may also require coordination between specific colleges or universities and the programs, in other states coordination is optional. From 2015 to 2016, seven states enacted legislation to create hemp research or pilot programs, including Pennsylvania (H.B. 976) and Hawaii (S.B. 2659).
No, as long as the plant is used correctly then no it’s not a bad thing. I’m sure there’s probably more good capability about that plant that people know or don’t know. No matter how it’s administered, as long as used properly it’s a good thing. It probably has more healing capabilities than people know about and since big Pharma or whoever it is out there discovered this, that’s probably why they made it illegal for all we know. Yes, I know there’s no money in cure which would hurt big Pharma but oh well! If they want to keep us away from the cure and keep us all sick, I say go for it anyway and go for the cure.

Thank you. I am 81 and started the CBD drops night and morning. I sleep better and no longer suffer the excruciating pain from diverticulitis. I saw somewhere that for my asthma I need the THC so got some (totally illegal here in South Africa). I think it is helping. The diagnosis of COPD was made some years ago and as a health psychologist I do all I can to remain healthy for my 97th birthday!! (Both my grandmother and greatgrandmother did so I believe I will too).